Valneva SE
VALN8.485USD
+0.125+1.50%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
1.38BMarket Cap
LossP/E TTM
More Details of Valneva SE Company
Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
Valneva SE Info
Ticker SymbolVALN
Company nameValneva SE
IPO dateJun 28, 2007
CEOLingelbach (Thomas)
Number of employees- -
Security typeDepository Receipt
Fiscal year-endJun 28
Address6, Rue Alain Bombard
CitySAINT-HERBLAIN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryFrance
Postal code44800
Phone33228073710
Websitehttps://valneva.com/
Ticker SymbolVALN
IPO dateJun 28, 2007
CEOLingelbach (Thomas)
Company Executives of Valneva SE
Name
Name/Position
Position
Shareholding
Change
Dr. Hanneke Schuitemaker
Dr. Hanneke Schuitemaker
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Dipal Patel
Ms. Dipal Patel
Chief Commercial Officer
Chief Commercial Officer
--
--
Ms. Anne-Marie Graffin
Ms. Anne-Marie Graffin
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Kathrin U. Jansen, Ph.D.
Dr. Kathrin U. Jansen, Ph.D.
Director
Director
--
--
Dr. Juan Carlos Jaramillo
Dr. Juan Carlos Jaramillo
Chief Medical Officer
Chief Medical Officer
--
--
Mr. James R. Sulat
Mr. James R. Sulat
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
Ms. Daniele Guyot-Caparros
Ms. Daniele Guyot-Caparros
Independent Director
Independent Director
--
--
Mr. James Connolly
Mr. James Connolly
Independent Director
Independent Director
--
--
Mr. Thomas Lingelbach
Mr. Thomas Lingelbach
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Peter Buehler
Mr. Peter Buehler
Chief Financial Officer
Chief Financial Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Hanneke Schuitemaker
Dr. Hanneke Schuitemaker
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Dipal Patel
Ms. Dipal Patel
Chief Commercial Officer
Chief Commercial Officer
--
--
Ms. Anne-Marie Graffin
Ms. Anne-Marie Graffin
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Kathrin U. Jansen, Ph.D.
Dr. Kathrin U. Jansen, Ph.D.
Director
Director
--
--
Dr. Juan Carlos Jaramillo
Dr. Juan Carlos Jaramillo
Chief Medical Officer
Chief Medical Officer
--
--
Mr. James R. Sulat
Mr. James R. Sulat
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
IXIARO
94.07M
55.47%
Third party products
33.19M
19.57%
DUKORAL
32.30M
19.05%
Chikungunya VLA1553
3.70M
2.18%
Others
1.13M
0.67%
Unallocated
704.00K
0.42%
By RegionUSD
Name
Revenue
Proportion
United States
48.59M
28.66%
Canada
32.32M
19.06%
United Kingdom
19.49M
11.49%
Germany
18.37M
10.84%
Austria
15.90M
9.37%
Other
34.91M
20.58%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
IXIARO
94.07M
55.47%
Third party products
33.19M
19.57%
DUKORAL
32.30M
19.05%
Chikungunya VLA1553
3.70M
2.18%
Others
1.13M
0.67%
Unallocated
704.00K
0.42%
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Novo Holdings A/S
2.73%
Frazier Life Sciences Management, L.P.
2.67%
General American Investors Company, Inc.
0.41%
Wells Fargo Advisors
0.18%
Marshall Wace LLP
0.04%
Other
93.97%
Shareholders
Shareholders
Proportion
Novo Holdings A/S
2.73%
Frazier Life Sciences Management, L.P.
2.67%
General American Investors Company, Inc.
0.41%
Wells Fargo Advisors
0.18%
Marshall Wace LLP
0.04%
Other
93.97%
Shareholder Types
Shareholders
Proportion
Venture Capital
2.73%
Private Equity
2.67%
Investment Advisor
0.47%
Research Firm
0.22%
Investment Advisor/Hedge Fund
0.04%
Hedge Fund
0.02%
Other
93.85%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
30
4.53M
5.58%
+3.61M
2025Q2
25
665.50K
0.82%
-300.83K
2025Q1
28
666.20K
0.82%
-333.59K
2024Q4
27
820.97K
1.18%
-47.15K
2024Q3
26
836.06K
1.21%
+31.78K
2024Q2
28
742.08K
1.07%
+162.52K
2024Q1
32
513.10K
0.74%
-47.53K
2023Q4
30
421.64K
0.61%
-110.65K
2023Q3
32
418.35K
0.60%
-285.66K
2023Q2
33
378.64K
0.55%
-602.57K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Novo Holdings A/S
2.38M
2.92%
+2.38M
--
Jun 30, 2025
Frazier Life Sciences Management, L.P.
1.46M
1.8%
+1.46M
--
Jun 30, 2025
General American Investors Company, Inc.
354.36K
0.44%
--
--
Jun 30, 2025
Wells Fargo Advisors
245.18K
0.3%
+1.96K
+0.81%
Jun 30, 2025
Ironwood Investment Management, LLC
25.14K
0.03%
+113.00
+0.45%
Jun 30, 2025
Morgan Stanley & Co. International Plc
6.54K
0.01%
+2.82K
+75.62%
Jun 30, 2025
Citadel Advisors LLC
35.74K
0.04%
+8.52K
+31.30%
Jun 30, 2025
Morgan Stanley Smith Barney LLC
1.48K
0%
--
--
Jun 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Valneva SE?
The top five shareholders of Valneva SE are:
Novo Holdings A/S holds 2.38M shares, accounting for 2.92% of the total shares.
Frazier Life Sciences Management, L.P. holds 1.46M shares, accounting for 1.80% of the total shares.
General American Investors Company, Inc. holds 354.36K shares, accounting for 0.44% of the total shares.
Wells Fargo Advisors holds 245.18K shares, accounting for 0.30% of the total shares.
Ironwood Investment Management, LLC holds 25.14K shares, accounting for 0.03% of the total shares.
Novo Holdings A/S holds 2.38M shares, accounting for 2.92% of the total shares.
Frazier Life Sciences Management, L.P. holds 1.46M shares, accounting for 1.80% of the total shares.
General American Investors Company, Inc. holds 354.36K shares, accounting for 0.44% of the total shares.
Wells Fargo Advisors holds 245.18K shares, accounting for 0.30% of the total shares.
Ironwood Investment Management, LLC holds 25.14K shares, accounting for 0.03% of the total shares.
What are the top three shareholder types of Valneva SE?
The top three shareholder types of Valneva SE are:
Novo Holdings A/S
Frazier Life Sciences Management, L.P.
General American Investors Company, Inc.
Novo Holdings A/S
Frazier Life Sciences Management, L.P.
General American Investors Company, Inc.
How many institutions hold shares of Valneva SE (VALN)?
As of 2025Q3, 30 institutions hold shares of Valneva SE, with a combined market value of approximately 4.53M, accounting for 5.58% of the total shares. Compared to 2025Q2, institutional shareholding has increased by 4.77%.
What is the biggest source of revenue for Valneva SE?
In FY2024, the IXIARO business generated the highest revenue for Valneva SE, amounting to 94.07M and accounting for 55.47% of total revenue.
